A retrospective cohort study assessing the weight gain in treatment-naïve, HIV-infected patients started on antiretroviral therapy
Latest Information Update: 07 Feb 2022
Price :
$35 *
At a glance
- Drugs Bictegravir (Primary) ; Dolutegravir (Primary) ; Elvitegravir (Primary) ; Raltegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 07 Feb 2022 New trial record